Review of consensus interferon in the treatment of chronic hepatitis C.
Consensus interferon (CIFN) is an artificially engineered interferon that reflects most of the human genotype 1 interferons and shows a higher biological and antiviral capacity in vitro. It has been used internationally to treat patients with chronic hepatitis C (HCV) infection before pegylated IFN became available. To mimic the half-life of PEG-IFN it has to be administered on a daily basis. The gold standard in the treatment of hepatitis C is well established and recommended. Today patients are being treated with a combination therapy of pegylated IFN and ribavirin. Length and dosage of therapy depends on the genotype of the virus. Patients with genotype 1 and 4 and high viral load should be treated for 48 weeks; for patients with these genotypes along with either low viral load or early virological response, therapy for 24 weeks is sufficient. Patients with genotype 2 and 3 should be treated for up to 24 weeks. However, daily dosing of IFN-alpha, eg, CIFN, resulting in a higher cumulative dosage, might be beneficial and more efficacious in some chronic HCV-infected patients. Patients with genotype 1, having initially high viral load (>800,000 IU/mL) and showing advanced liver disease with progressive fibrosis or even cirrhosis comprise the difficult-to-treat in order to overcome the infection. This review summarizes and critically discusses the published data on the treatment of HCV with CIFN.
Witthöft
Th
T
University Hospital Schleswig Holstein, Campus Lübeck, Dept of Medicine I, Division of Gastroenterology, Lübeck, Germany.
Hepatology. 1997 Jul;26(1):226-31
9214474
Keio J Med. 2006 Sep;55(3):111-7
17008803
Liver Int. 2006 Apr;26(3):319-25
16584394
Rev Gastroenterol Disord. 2004;4 Suppl 1:S22-30
15184821
Am J Gastroenterol. 1999 Sep;94(9):2496-500
10484014
Am J Gastroenterol. 1999 Dec;94(12):3583-8
10606323
Am J Gastroenterol. 2000 Nov;95(11):3225-9
11095346
J Hepatol. 2006 Feb;44(2):291-301
16360972
J Viral Hepat. 2003 Jan;10(1):43-9
12558911
Turk J Gastroenterol. 2006 Mar;17(1):35-9
16830275
J Viral Hepat. 1998 Jul;5(4):271-6
9751014
Hepatology. 1999 Jul;30(1):271-6
10385666
J Endocrinol Invest. 2002 Jul-Aug;25(7):624-30
12150338
J Interferon Cytokine Res. 1996 Jul;16(7):489-99
8836913
Curr Gastroenterol Rep. 2002 Feb;4(1):23-30
11825538
Hepatology. 1997 Sep;26(3 Suppl 1):101S-107S
9305673
Cytokines Cell Mol Ther. 1999 Dec;5(4):211-6
10850385
J Gastroenterol Hepatol. 2000 Dec;15(12):1418-23
11197053
Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947
15057741
J Clin Gastroenterol. 2004 Aug;38(7):599-604
15232365
Dig Dis Sci. 2007 Jun;52(6):1540-7
17406822
Cytokines Cell Mol Ther. 1999 Dec;5(4):207-10
10850384
Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4 Suppl 1:S3-9
17235282
J Viral Hepat. 2003 Jan;10(1):55-60
12558913
Lancet. 2001 Sep 22;358(9286):958-65
11583749
J Viral Hepat. 2002 Sep;9(5):334-9
12225327
Hepatology. 1997 Sep;26(3):747-54
9303508
Hepatology. 2002 Nov;36(5 Suppl 1):S121-7
12407585
J Hepatol. 2003 Nov;39(5):843-9
14568269
Intern Med. 2007;46(8):473-6
17443037
World J Gastroenterol. 2006 Nov 14;12(42):6861-4
17106937
Aliment Pharmacol Ther. 2001 Apr;15(4):551-7
11284785
World J Gastroenterol. 2007 Jan 28;13(4):579-84
17278224
Hepatology. 1998 Apr;27(4):1136-43
9537455
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
J Gastroenterol. 2002;37(9):732-6
12375147
Semin Oncol. 1997 Jun;24(3 Suppl 9):S9-4-S9-17
9208870
Dig Dis Sci. 2005 Apr;50(4):727-32
15844709
J Gastroenterol Hepatol. 2000 Oct;15(10):1165-70
11106097
Hepatol Res. 2001 Mar 26;19(3):284-293
11251311
Hepatology. 1999 Aug;30(2):562-6
10421669
Can J Gastroenterol. 2003 Aug;17(8):479-82
12945008